ニュース

In an editorial article published in the New England Journal of Medicine, Dr. Vinay Prasad, the newly appointed head of the ...
"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...
The FDA announced it will limit access to Covid-19 vaccines going forward to people 65 and older and others at high risk of ...
It comes as Health Secretary Robert F. Kennedy Jr. and his appointees continue to scrutinize the use of vaccines for a number ...
Top officials in the Trump administration on Tuesday announced they will limit the approval of new COVID-19 vaccines to ...
FDA officials outlined new restrictions for COVID-19 vaccine approvals in the United States that could limit their use among ...
The FDA also gave full approval to the Novavax COVID vaccine (Nuvaxovid) using this approach, approving it for those ages 65 ...
Agency leaders said there was evidence to justify approval only for older people and those with medical conditions. Many ...
The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...
After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...
(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...
The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.